Intriguingly, endpoint analysis of the breast cancer cohort in this study determined that there was more pronounced activity in BRCA1/2 mutant patients, as determined by ORR rates of 47% compared to 11% and PFS of 8.3 months versus 2.1 months, respectively. This evidence concerns the gene BRCA1 and breast carcinoma.